Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset NVST
Coverage 166,827 Raw stories ingested 21,951 rewritten in CS_CZ • 0 to rewrite (last 2 days).
Agents 7 waiting Pipeline agents
  • FMP Stock News Fetch every minute 39s ago
  • FMP Forex News Fetch every 5 min 1m ago
  • CoinGecko News Fetch every 5 min 3m ago
  • FIO Stock News Fetch every 10 min 6m ago
  • Patria Stock News Fetch every 10 min 6m ago
  • Editorial rewrite Rewrite every minute 39s ago
  • Asset sync Assets every 1 hour 55m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Language
Relevance
Clear
Details Date Content Source Relevance
2026-09-04 17:33 5d ago
2026-09-04 12:37 5d ago
Envista po silných čtvrtletních výsledcích mírně roste
NVST Envista Holdings
FMP Stock News 72
Original source text
It has been about a month since the last earnings report for Envista (NVST - Free Report) . Shares have added about 0.8% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Envista due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

Envista Tops Q2 Earnings and RevenuesEnvista Holdings Corporation reported adjusted earnings per share of 41 cents in the second quarter of 2026, up 57.7% year over year. The bottom line surpassed the Zacks Consensus Estimate by 24.24%.

The adjustments include non-cash charges related to the amortization of acquisition-related and other intangible assets, restructuring costs and asset impairments, fair-value adjustment of acquisition-related inventory and tariff refunds, among others.

The company’s GAAP earnings were 33 cents compared with the year-ago quarter’s earnings of 16 cents per share.

NVST’s Revenues

Revenues totaled $730.5 million in the reported quarter, up 7.1% year over year. The metric topped the Zacks Consensus Estimate by 2.17%.

Segment-wise, Specialty Products & Technologies sales totaled $471 million, up 5.8% year over year. Revenues from Equipment & Consumables rose 9.5% year over year to $259.5 million in the quarter under review.

NVST’s Operational Update

The gross profit in the reported quarter climbed 10% year over year to $407 million. The gross margin expanded 149 basis points (bps) to 55.7% despite cost of sales increasing 3.6%.

Selling, general and administrative expenses were up 0.3% year over year to $296.3 million. Research and development expenses rose 7.4% year over year to $30.4 million. The operating profit of $80.3 million jumped 73.4% year over year. The operating margin expanded 420 bps to 11%.

NVST’s Financial Update

Envista ended the second quarter of 2026 with cash and cash equivalents of $1.13 billion compared with $1.08 billion as of Apr. 3. Long-term debt in the second quarter was $1.44 billion compared with $1.43 billion at the end of first quarter. Cumulative net cash provided by operating activities as of July 3, 2026 was $115.9 million compared with $89 million a year ago.

Envista’s 2026 Guidance

For 2026, the company expects core sales growth between 3.5% and 4.5% (previously, 2%-4%). The Zacks Consensus Estimate projects 2026 sales to be $2.88 billion, representing 6% growth over 2025.

Adjusted EBITDA growth is projected in the range of 11%-14%, previously 7%-13%.

Adjusted diluted earnings per share are projected between $1.50 and $1.55 (earlier, $1.35 to $1.45). The consensus mark for the metric stands at $1.53.

Free cash flow conversion is expected to be approximately 100%.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates review.

VGM ScoresAt this time, Envista has a subpar Growth Score of D, a score with the same score on the momentum front. However, the stock has a grade of B on the value side, putting it in the second quintile for value investors.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Envista has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry PlayerEnvista belongs to the Zacks Medical - Products industry. Another stock from the same industry, Neogen (NEOG - Free Report) , has gained 3% over the past month. More than a month has passed since the company reported results for the quarter ended May 2026.

Neogen reported revenues of $225.3 million in the last reported quarter, representing a year-over-year change of -0.1%. EPS of $0.09 for the same period compares with $0.05 a year ago.

For the current quarter, Neogen is expected to post earnings of $0.05 per share, indicating a change of +25% from the year-ago quarter. The Zacks Consensus Estimate has changed +4.4% over the last 30 days.

Neogen has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.
2026-08-31 18:34 9d ago
2026-08-31 04:01 9d ago
Canada Pension Plan koupila podíl v Envista
NVST Envista Holdings
FMP Stock News 72
Original source text
Canada Pension Plan Investment Board acquired a new position in Envista Holdings Corporation (NYSE:NVST – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 191,353 shares of the company’s stock, valued at approximately $5,042,000. Canada Pension Plan Investment Board owned about 0.12% of Envista at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. GSA Capital Partners LLP bought a new position in Envista in the second quarter valued at $2,039,000. Pzena Investment Management LLC bought a new stake in Envista during the second quarter worth about $30,494,000. Dimensional Fund Advisors LP boosted its holdings in shares of Envista by 1.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 9,780,948 shares of the company’s stock worth $248,130,000 after purchasing an additional 152,488 shares in the last quarter. SummitTX Capital L.P. purchased a new stake in Envista in the first quarter worth approximately $4,268,000. Finally, Principal Financial Group Inc. boosted its stake in shares of Envista by 36.8% in the 1st quarter. Principal Financial Group Inc. now owns 483,983 shares of the company’s stock valued at $12,279,000 after purchasing an additional 130,237 shares in the last quarter.

Wall Street Analysts Forecast Growth A number of brokerages have issued reports on NVST. JPMorgan Chase & Co. raised their price target on shares of Envista from $26.00 to $29.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. Weiss Ratings raised Envista from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 6th. Zacks Research raised shares of Envista from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Wall Street Zen raised Envista from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 22nd. Finally, Morgan Stanley set a $23.00 target price on shares of Envista in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.31.

Check Out Our Latest Stock Analysis on NVST Envista Stock Performance NYSE NVST opened at $27.15 on Monday. Envista Holdings Corporation has a twelve month low of $18.77 and a twelve month high of $30.42. The business has a 50-day moving average price of $27.12 and a 200-day moving average price of $26.35. The company has a quick ratio of 2.07, a current ratio of 2.43 and a debt-to-equity ratio of 0.47. The firm has a market cap of $4.36 billion, a price-to-earnings ratio of 46.81, a price-to-earnings-growth ratio of 1.29 and a beta of 0.86.

Envista (NYSE:NVST – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. The firm had revenue of $730.50 million during the quarter, compared to analyst estimates of $716.11 million. Envista had a net margin of 3.33% and a return on equity of 7.88%. Envista’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.26 earnings per share. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. As a group, equities research analysts predict that Envista Holdings Corporation will post 1.53 EPS for the current fiscal year.

Insider Activity at Envista In related news, SVP Mischa Reis sold 8,000 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total value of $220,000.00. Following the completion of the transaction, the senior vice president directly owned 27,321 shares of the company’s stock, valued at approximately $751,327.50. This trade represents a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.99% of the company’s stock.

About Envista (Free Report)

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.

See Also Five stocks we like better than Envista Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding NVST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Envista Holdings Corporation (NYSE:NVST – Free Report).

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
2026-08-13 15:03 27d ago
2026-08-13 10:05 27d ago
NVST zvýšila EPS, upravený zisk i výhled
NVST Envista Holdings
FMP Stock News 78
Original source text
Key Takeaways NVST's Q2 adjusted EPS jumped 57.7%, while operating profit rose 73.4% and margins expanded.NVST raised adjusted earnings guidance to $1.50-$1.55 and EBITDA growth guidance to 11%-14%.NVST faces China pricing pressure, tariffs and uneven product trends that could temper further upside. Envista Holdings Corporation (NVST - Free Report) is showing a sharper earnings recovery after a solid second quarter, with stronger profitability and raised 2026 guidance strengthening the near-term case.

The offset is valuation. NVST now trades above its five-year median forward earnings multiple, leaving less room for execution setbacks even as operating momentum improves.

NVST’s Earnings Recovery Supports the Bull CaseAdjusted earnings were 41 cents per share in the second quarter of 2026, up 57.7% year over year. Operating profit rose 73.4% to $80.3 million, while the operating margin expanded 420 basis points to 11%.

The Zacks Consensus Estimate calls for 2026 earnings of $1.53 per share, up from $1.19 in 2025. Management also raised adjusted earnings guidance to $1.50-$1.55 and adjusted EBITDA growth guidance to 11%-14%, reinforcing expectations for a meaningful profit recovery.

Image Source: Zacks Investment Research

Envista’s Valuation Leaves Less Room for ErrorNVST trades at 18.0X forward 12-month earnings, above its five-year median of 17.5X and the Zacks sub-industry’s 16.2X. That premium suggests investors are already assigning value to the improving earnings trajectory.

The picture is not uniformly expensive. NVST’s multiple remains below the Zacks Medical sector’s 20.5X and the S&P 500’s 20.7X. Still, with the stock above its own historical median, further upside may depend more heavily on sustained execution.

Image Source: Zacks Investment Research

NVST’s Growth Drivers Extend Beyond One QuarterSecond-quarter core sales increased 5%. Equipment & Consumables core sales rose 8.5%, supported by high-single-digit growth in consumables and diagnostics, while Spark grew at a double-digit rate and implants advanced at a low-single-digit pace.

New products and the Versah acquisition add more growth avenues. Align Technology, Inc. (ALGN - Free Report) reported an 8.2% year-over-year increase in second-quarter 2026 clear aligner revenues, showing continued activity in a category where Spark competes. DENTSPLY SIRONA Inc. (XRAY - Free Report) , another diversified dental-products company, reported $898 million in second-quarter 2026 net sales and reiterated its 2026 outlook.

Envista’s Risks Could Limit Further Re-RatingChina pricing remains a major uncertainty. Management expects the orthodontic volume-based procurement program to produce a large price reduction, while the second implant program could reduce prices by about 10%-15%.

Tariff costs increased about $5 million year over year in the second quarter and are expected to remain at similar quarterly levels in the second half. Brackets and wires also declined at a high-single-digit rate, highlighting uneven performance across the portfolio.

NVST’s Style Profile Favors Value and MomentumThe investment case has improved, but the above-median valuation raises the bar for continued earnings delivery. Investors weighing the stock now have stronger operating trends on one side and policy, tariff and product-execution risks on the other.

NVST currently carries a Zacks Rank #1 (Strong Buy). It also has a Value Score of B, Momentum Score of B and VGM Score of B, all favorable readings when paired with a top Zacks Rank. Its Growth Score of D is the main counterweight, reflecting a less favorable growth profile despite the current earnings rebound.

You can see the complete list of today's Zacks #1 Rank stocks here.
2026-08-09 00:20 1mo ago
2026-08-08 18:05 1mo ago
Envista zvýšila výhled po silném 2. čtvrtletí
NVST Envista Holdings
FMP Stock News 92
Original source text
Envista NYSE: NVST reported second-quarter 2026 sales of $731 million, supported by 5% core revenue growth and contributions from foreign exchange and acquisitions that lifted total revenue growth to just over 7%.

President and Chief Executive Officer Paul Keel said the company delivered balanced growth across its two reporting segments and major geographies, while the dental market remained resilient amid macroeconomic pressure. The company reported 7% core growth for the first half of 2026.

Adjusted EBITDA increased 28% year over year, while adjusted EBITDA margin expanded 230 basis points to 14.7%. Adjusted earnings per share rose 58% to $0.41. The company generated $105 million in free cash flow during the quarter, representing 158% conversion, and repurchased approximately 2.4 million shares at an average price of $24 per share.

Get Envista alerts:

Segment growth led by equipment and consumables Equipment and Consumables posted 8.5% core sales growth, with high-single-digit growth in both consumables and diagnostics. Keel said consumables benefited from its relative insulation from macro volatility because its products support procedures that are typically covered by insurance. Diagnostics also benefited from a market recovery following a multiyear post-COVID contraction, he said.

Keel said Envista estimates the consumables and diagnostics markets grew at mid-single-digit rates during the first half, while the company’s businesses grew at high-single-digit to low-double-digit rates. He attributed the outperformance to share gains, commercial and operational initiatives, and new-product activity.

Specialty Products & Technologies reported 3.1% core sales growth and nearly 6% total revenue growth. Spark clear aligners again delivered double-digit growth, or high-single-digit growth after accounting for changes in revenue deferrals. Implant core sales increased by low single digits, while brackets and wires declined by high single digits against a prior-year comparison that benefited from customer purchases ahead of tariff and pricing actions.

Adjusted operating profit in Specialty Products & Technologies increased $9 million, or 15%, and segment margin improved 120 basis points. Equipment and Consumables adjusted operating profit increased 25%, with operating margin rising 250 basis points, driven by pricing, volume and foreign-exchange benefits.

New products and investment initiatives During the quarter, Envista launched ZenSeal Pro, a bioceramic endodontic sealer used in root canal procedures, and Demi Pro, a lightweight cordless curing light for restorative procedures. Keel said the company expects the launches to build on recent consumables share gains.

In orthodontics, Envista expanded Ormco Digital Bonding, or ODB, to all of its bracket systems. The digital platform was initially launched in 2023 with the Damon Ultima system. Keel said the expanded offering makes Envista the only scaled player offering complete solutions across both clear aligners and fixed orthodontics.

The company also discussed ongoing implant investments. Keel said the S-series implant launch introduced in the first quarter was ahead of plan, with roughly one-quarter of sales coming from competitive conversions. An abutments product is available in Europe and could launch in North America during the second half, subject to regulatory approvals. The company’s Versah acquisition, which added osseodensification technology, is also performing ahead of its acquisition plan, according to Keel.

China VBP expectations and second-half cadence Envista expects China’s volume-based procurement processes for orthodontics, or VBP1, and implants, or VBP2, to occur in the second half of 2026. Management incorporated that assumption into its revised outlook.

Keel said Envista expects orthodontics VBP1 to result in price compression similar to the first implant VBP, which saw prices decline by roughly 45%, although he said the company expects share gains. For implant VBP2, Envista expects a smaller price decline of approximately 10% to 15%.

Management expects China to grow moderately in the second half, with somewhat stronger growth in the fourth quarter. Chief Financial Officer Eric Hammes said the company has maintained a lean channel position and expects its global presence, supply chain and market position to support a post-VBP response. He said Envista was down year over year in China during the first half.

Hammes also said the company expects approximately 3.5% core growth in the second half on a normalized basis. Reported fourth-quarter core growth is expected to be flat to slightly down because the quarter will have four fewer selling days than the prior-year period. Excluding the calendar effect, the company expects fourth-quarter core growth to align with its full-year guidance range.

Raised full-year outlook Envista raised and narrowed its 2026 guidance, now expecting:

Core sales growth of 3.5% to 4.5%. Adjusted EBITDA growth of 11% to 14%. Adjusted EPS of $1.50 to $1.55. Free cash flow conversion of approximately 100% of adjusted net income. Hammes said the company expects foreign-exchange effects on both revenue and profit to be nominal to near zero in the second half, assuming currency rates remain near recent levels. He also said Envista now expects a full-year non-GAAP tax rate of about 26%, about two percentage points below its initial guidance.

Looking ahead, Envista plans to hold an investor day on Sept. 17, where management said it will provide an update on the value-creation plan introduced in March 2025, financial progress and innovation priorities across its four main businesses.

About Envista (NYSE:NVST)Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company's offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista's product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Envista Right Now?Before you consider Envista, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.

While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
2026-08-05 21:44 1mo ago
2026-08-05 16:05 1mo ago
Envista zvýšila tržby i celoroční výhled
NVST Envista Holdings
FMP Stock News 92
Original source text
, /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended July 3, 2026.

"We built on our fast start in Q1 with continued good performance in Q2," said Paul Keel, CEO. "We delivered growth across both our reporting segments and all major geographies. Our focus on operational excellence, underpinned by the Envista Business System, contributed to further margin expansion. Based on our strong first-half performance and continued momentum, we are raising our full year outlook for core sales growth, adjusted EBITDA, and adjusted EPS. We are well-positioned to deliver another year of progress and performance."

Second Quarter Financial Highlights

Sales were $731 million, with core sales growth of 5.0% over the second quarter of 2025. GAAP diluted EPS of $0.33 and adjusted diluted EPS of $0.41 (+58% year-on-year) GAAP Net Income of $54 million and adjusted EBITDA of $108 million (+28% year-on-year), with an adjusted EBITDA margin of 14.7% (+230 bps year-on-year) Second Quarter Business Highlights

Growth: In the context of macro uncertainty, both reporting segments delivered positive growth, with 3.1% core growth in Specialty Products & Technologies and 8.5% core growth in Equipment and Consumables. Operations: Ongoing contributions from the Envista Business System (EBS) supporting 70 bps of adjusted gross margin and 230 bps of adjusted EBITDA margin expansion. People: Continued to advance our high-performing, continuous improvement culture through numerous customer, employee, and charitable events around the world. Net Income, EBITDA, and EPS (in millions, except per share amounts):

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

GAAP Net Income

$                   54

$                   26

$                   92

$                   44

Adjusted Net Income

$                   67

$                   44

$                 126

$                   85

Adjusted EBITDA

$                 108

$                   84

$                 207

$                 163

GAAP Diluted Earnings Per Share

$                0.33

$                0.16

$                0.56

$                0.26

Adjusted Diluted Earnings Per Share

$                0.41

$                0.26

$                0.77

$                0.50

Cash Flow:

Operating cash flow for the second quarter of 2026 was $119 million and free cash flow was $105 million, compared to $89 million and $76 million in the second quarter of 2025, respectively. 

Share Repurchases:

During the quarter ended July 3, 2026, we repurchased 2.4 million shares for approximately $59 million. At the end of the quarter, we had approximately $283 million remaining repurchase capacity under our stock repurchase program.

Outlook:

We are updating our guidance for the full year 2026:

Current 2026 Guidance

Prior 2026 Guidance

Core Sales Growth

3.5% to 4.5%

2% to 4%

Adjusted EBITDA Growth

11% to 14%

7% to 13%

Adjusted Diluted Earnings Per Share

$1.50 to $1.55

$1.35 to $1.45

Free Cash Flow Conversion

~100%

~100%

Please note, we do not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.

We will discuss our quarterly results and provide details on our outlook for 2026 during an investor conference call on August 5, 2026, starting at 2:00 P.M. PT. The call and an accompanying slide presentation will be webcast on the "Investors" section of our website, www.envistaco.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of our website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 800-836-8184 within the U.S. or +1 646-357-8785 outside the U.S. a few minutes before 2:00 PM PT and referencing conference ID #73468.  A replay of the conference call will be available shortly after the conclusion of the call. You can access the replay dial-in information on the "Investors" section of our website under the subheading "Events & Presentations." Presentation materials relating to our results have been posted to the "Investors" section of our website under the subheading "Quarterly Earnings".

ABOUT ENVISTA

Envista is a global leader in the dental industry, uniting more than 30 trusted brands—including DEXIS, Kerr, Nobel Biocare, and Ormco—under one mission: partnering with dental professionals to improve patients' lives. With a heritage of category-defining innovation, our brands have shaped modern dentistry: Nobel Biocare introduced the first dental implant, Ormco is a pioneer in both traditional and digital orthodontics, DEXIS has long been at the forefront of 2D, 3D and intraoral imaging, and Kerr has supported clinicians for over 135 years. Our high-performing culture is underpinned by our CIRCLe Values and the Envista Business System. Guided by these, we deliver a comprehensive portfolio of technologies, consumables, and services that empower clinicians to provide confident, efficient care—today and for the future. Learn more at http://envistaco.com. 

NON-GAAP MEASURES

All "Adjusted" amounts including core sales growth and free cash flow are non-GAAP items. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these non-GAAP measures are included in the attached supplemental schedules. We do not reconcile forward looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions, discontinued products, and any other potential adjustments which would be reflected in any forecasted GAAP measure.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the conditions in the U.S. and global economy, the impact of inflation and increasing interest rates, slower economic growth or recession, international economic, political, legal, compliance and business factors, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations including tariffs or other impositions on imported goods, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war (including supply chain disruptions), terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, security breaches or other disruptions affecting our external information technology contractors, vendors or other service providers, our growing use of artificial intelligence systems to automate processes and analyze data, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to impairment charges for our goodwill and intangible assets, changes in accounting standards and subjective assumptions, estimates and judgment by management, currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2025 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

CONTACT
Jim Gustafson
Vice President, Investor Relations
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
[email protected]

ENVISTA HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
($ and shares in millions, except per share amounts)

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

Sales

$           730.5

$           682.1

$         1,436.0

$          1,299.0

Cost of sales

323.5

312.2

638.9

593.1

Gross profit

407.0

369.9

797.1

705.9

Operating expenses:

Selling, general and administrative

296.3

295.3

593.9

567.0

Research and development

30.4

28.3

60.4

53.6

Operating profit

80.3

46.3

142.8

85.3

Nonoperating (expense) income:

Other income (expense), net

2.8

2.4

(0.1)

1.7

Interest expense, net

(8.7)

(8.0)

(16.1)

(17.3)

Income before income taxes

74.4

40.7

126.6

69.7

Income tax expense

20.7

14.3

34.2

25.3

Net income

$             53.7

$             26.4

$             92.4

$             44.4

Earnings per share:

Earnings - basic

$             0.33

$             0.16

$             0.57

$             0.26

Earnings - diluted

$             0.33

$             0.16

$             0.56

$             0.26

Average common stock and common equivalent
shares outstanding:

Basic

161.9

169.0

162.9

170.7

Diluted

164.1

169.9

165.3

171.7

ENVISTA HOLDINGS CORPORATION 
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
($ in millions, except share amounts)

As of

July 3, 2026

December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents

$           1,125.6

$        1,211.7

     Trade accounts receivable, less allowance for credit losses of $21.8 and $22.5,
      respectively

436.9

429.6

Inventories, net

290.9

288.1

Prepaid expenses and other current assets

104.6

97.2

Total current assets

1,958.0

2,026.6

Property, plant and equipment, net

295.7

296.8

Operating lease right-of-use assets

146.2

142.1

Other long-term assets

230.4

228.1

Goodwill

2,353.5

2,358.2

Other intangible assets, net

613.3

627.2

Total assets

$           5,597.1

$        5,679.0

LIABILITIES AND EQUITY

Current liabilities:

Trade accounts payable

190.2

191.6

Accrued expenses and other liabilities

578.6

622.0

Operating lease liabilities

38.5

39.0

Total current liabilities

807.3

852.6

Operating lease liabilities

113.2

110.4

Other long-term liabilities

164.0

161.4

Long-term debt

1,436.3

1,448.3

Commitments and contingencies

Stockholders' equity:

Preferred stock, $0.01 par value, 15.0 million shares authorized; no shares issued
or outstanding at July 3, 2026 and December 31, 2025





Common stock, $0.01 par value, 500.0 million shares authorized; 176.4 million
shares issued and 160.6 million shares outstanding at July 3, 2026; 175.4 million
shares issued and 163.8 million shares outstanding at December 31, 2025

1.8

1.8

Treasury stock at cost; 15.8 million shares and 11.6 million shares at July 3, 2026
and December 31, 2025, respectively

(333.7)

(224.5)

Additional paid-in capital

3,906.1

3,882.6

Accumulated deficit

(348.0)

(440.4)

Accumulated other comprehensive loss

(149.9)

(113.2)

Total stockholders' equity

3,076.3

3,106.3

Total liabilities and stockholders' equity

$           5,597.1

$        5,679.0

ENVISTA HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
($ in millions)

Six Months Ended

July 3, 2026

June 27, 2025

Cash flows from operating activities:

Net income

$              92.4

$              44.4

Noncash items:

Depreciation

20.8

19.9

Amortization

36.2

37.8

Allowance for credit losses

5.8

4.0

Stock-based compensation expense

19.7

16.8

Gain on investments in rabbi trust, net

(1.9)

(1.6)

Loss on equity investments

2.0



(Gain) loss on sale of property, plant and equipment

(2.7)

0.3

Restructuring charges

0.9

0.2

Fixed assets impairments and other charges

0.9

1.4

Non-cash operating lease costs

18.5

17.2

Amortization of debt discount and issuance costs

2.0

2.2

 Deferred income taxes



(0.9)

Change in trade accounts receivable

(14.5)

(37.2)

Change in inventories

(0.9)

(23.5)

Change in trade accounts payable

0.1

(10.0)

Change in prepaid expenses and other assets

(7.3)

(4.3)

Change in accrued expenses and other liabilities

(32.4)

44.5

Change in operating lease liabilities

(23.7)

(22.2)

Net cash provided by operating activities

115.9

89.0

Cash flows from investing activities:

Payments for additions to property, plant and equipment

(27.4)

(18.2)

Purchases of investments held in rabbi trust

(3.7)

(1.0)

Proceeds from sale of investments held in rabbi trust

1.5

0.9

Proceeds from sales of property, plant and equipment

0.9

0.5

Acquisitions, net of cash acquired

(54.4)



All other investing activities, net

(0.1)

(8.1)

Net cash used in investing activities

(83.2)

(25.9)

Cash flows from financing activities:

Proceeds from stock option exercises

4.0

1.5

Cash paid for treasury stock under the stock repurchase program

(103.0)

(100.3)

Treasury stock purchases related to tax withholding on equity awards

(6.9)

(4.3)

Principal paid related to exchange of convertible notes due 2025



(116.3)

Proceeds from revolving line of credit



115.4

All other financing activities

(0.4)



Net cash used in financing activities

(106.3)

(104.0)

Effect of exchange rate changes on cash and cash equivalents

(12.5)

82.4

Net change in cash and cash equivalents

(86.1)

41.5

Beginning balance of cash and cash equivalents

1,211.7

1,069.1

Ending balance of cash and cash equivalents

$          1,125.6

$           1,110.6

ENVISTA HOLDINGS CORPORATION
SUMMARY OF FINANCIAL METRICS (Unaudited)
($ in millions, except per share amounts)

GAAP

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

Gross Profit

$            407.0

$           369.9

$        797.1

$         705.9

Operating Profit

$              80.3

$             46.3

$        142.8

$           85.3

Net Income

$              53.7

$             26.4

$          92.4

$           44.4

Diluted Earnings Per Share

$              0.33

$             0.16

$          0.56

$           0.26

Operating Cash Flow

$            119.2

$             88.7

$        115.9

$           89.0

NON-GAAP *

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

Adjusted Gross Profit

$            402.2

$           371.2

$        795.8

$        709.5

Adjusted Operating Profit

$              94.5

$             71.1

$        183.9

$        141.7

Adjusted Net Income

$              66.5

$             43.7

$        126.5

$          85.2

Adjusted Diluted EPS

$              0.41

$             0.26

$          0.77

$          0.50

Adjusted EBITDA

$            107.7

$             84.3

$        206.6

$        163.3

Free Cash Flow

$            105.1

$             76.4

$          89.4

$          71.3

*

For information on non-GAAP measures see "Reconciliation of GAAP to Non-GAAP Financial Measures" below. Also see the accompanying "Notes to Reconciliation of GAAP to Non-GAAP Financial Measures."

ENVISTA HOLDINGS CORPORATION
SEGMENT INFORMATION (Unaudited)
($ in millions)

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

Sales

Specialty Products & Technologies

$           471.0

$           445.1

$        928.8

$        845.4

Equipment & Consumables

259.5

237.0

507.2

453.6

Total

$           730.5

$           682.1

$      1,436.0

$      1,299.0

Operating Profit (Loss)

Specialty Products & Technologies

$             60.1

$             45.3

$        106.6

$          82.9

Equipment & Consumables

45.9

36.1

92.7

68.0

Other

(25.7)

(35.1)

(56.5)

(65.6)

Total

$             80.3

$             46.3

$        142.8

$          85.3

Operating Margins

Specialty Products & Technologies

12.8 %

10.2 %

11.5 %

9.8 %

Equipment & Consumables

17.7 %

15.2 %

18.3 %

15.0 %

Total

11.0 %

6.8 %

9.9 %

6.6 %

ENVISTA HOLDINGS CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)
($ and shares in millions, except per share amounts)

Adjusted Gross Profit and Adjusted Gross Margin

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

Gross Profit

$         407.0

$         369.9

$         797.1

$        705.9

Restructuring costs and asset impairments A

7.3

0.3

10.4

2.2

Fair value adjustment of acquisition-related
inventory B

0.5

1.0

0.9

1.4

    Tariff refunds C

(12.6)



(12.6)



Adjusted Gross Profit

$         402.2

$         371.2

$         795.8

$        709.5

Gross Margin (Gross Profit / Sales)

55.7 %

54.2 %

55.5 %

54.3 %

Adjusted Gross Margin (Adjusted Gross Profit / Sales)

55.1 %

54.4 %

55.4 %

54.6 %

Adjusted Operating Profit

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

Consolidated

Operating Profit

$          80.3

$          46.3

$         142.8

$          85.3

Amortization of acquisition-related and other
intangible assets

17.4

19.0

36.2

37.8

Restructuring costs and asset impairments A

8.9

4.7

16.3

16.1

Fair value adjustment of acquisition-related
inventory B

0.5

1.0

0.9

1.4

    Tariff refunds C

(12.6)



(12.6)



Litigation settlement D







0.8

Acquisition-related expenses E



0.1

0.3

0.3

Adjusted Operating Profit

$          94.5

$          71.1

$         183.9

$         141.7

Adjusted Operating Profit as a % of Sales

12.9 %

10.4 %

12.8 %

10.9 %

Specialty Products & Technologies

Operating Profit

$          60.1

$          45.3

$         106.6

$          82.9

Amortization of acquisition-related and other
intangible assets

15.3

14.8

30.9

29.4

Restructuring costs and asset impairments A

6.1

0.1

10.5

4.3

    Tariff refunds C

(12.2)



(12.2)



Adjusted Operating Profit

$          69.3

$          60.2

$         135.8

$         116.6

Adjusted Operating Profit as a % of Sales

14.7 %

13.5 %

14.6 %

13.8 %

Equipment & Consumables

Operating Profit

$          45.9

$          36.1

$          92.7

$          68.0

Amortization of acquisition-related and other
intangible assets

2.1

4.2

5.3

8.4

Restructuring costs and asset impairments A

4.2

1.2

6.2

3.5

    Tariff refunds C

(0.4)



(0.4)



Litigation settlement D







0.8

Adjusted Operating Profit

$          51.8

$          41.5

$         103.8

$          80.7

Adjusted Operating Profit as a % of Sales

20.0 %

17.5 %

20.5 %

17.8 %

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

Adjusted Net Income

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

Net Income

$            53.7

$            26.4

$            92.4

$            44.4

Amortization of acquisition-related and other
intangible assets

17.4

19.0

36.2

37.8

Restructuring costs and asset impairments A

8.9

4.7

16.3

16.1

Fair value adjustment of acquisition-related
inventory B

0.5

1.0

0.9

1.4

    Tariff refunds C

(12.6)



(12.6)



Litigation settlement D







0.8

Acquisition-related expenses E



0.1

0.3

0.3

Loss on equity investments F





2.0



Tax effect of adjustments reflected above G

(2.8)

(6.2)

(10.6)

(15.0)

Discrete tax adjustments and other tax-related
adjustments H

1.4

(1.3)

1.6

(0.6)

Adjusted Net Income

$            66.5

$            43.7

$           126.5

$            85.2

Adjusted Diluted Earnings Per Share

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

Diluted Earnings Per Share

$            0.33

$            0.16

$            0.56

$            0.26

Amortization of acquisition-related and other
intangible assets

0.11

0.11

0.22

0.22

Restructuring costs and asset impairments A

0.05

0.03

0.10

0.09

Fair value adjustment of acquisition-related
inventory B



0.01

0.01

0.01

    Tariff refunds C

(0.08)



(0.08)



Litigation settlement D







0.01

Acquisition-related expenses E









Loss on equity investments F





0.01



Tax effect of adjustments reflected above G

(0.01)

(0.04)

(0.06)

(0.09)

Discrete tax adjustments and other tax-related
adjustments H

0.01

(0.01)

0.01



Adjusted Diluted Earnings Per Share

$            0.41

$            0.26

$            0.77

$            0.50

Adjusted EBITDA

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

Net Income

$          53.7

$          26.4

$          92.4

$          44.4

Interest expense, net

8.7

8.0

16.1

17.3

Income tax expense

20.7

14.3

34.2

25.3

Depreciation

10.4

10.8

20.8

19.9

Amortization of acquisition-related and other
intangible assets

17.4

19.0

36.2

37.8

Restructuring costs and asset impairments A

8.9

4.7

16.3

16.1

Fair value adjustment of acquisition-related
inventory B

0.5

1.0

0.9

1.4

    Tariff refunds C

(12.6)



(12.6)



Litigation settlement D







0.8

Acquisition-related expenses E



0.1

0.3

0.3

Loss on equity investments F





2.0



Adjusted EBITDA

$         107.7

$          84.3

$         206.6

$         163.3

Adjusted EBITDA as a % of Sales

14.7 %

12.4 %

14.4 %

12.6 %

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

Core Sales Growth 1

Consolidated

% Change Three Month
Period Ended July 3, 2026 vs.
Comparable 2025 Period

% Change Six Month Period
Ended July 3, 2026 vs.
Comparable 2025 Period

Total sales growth

7.1 %

10.5 %

Plus the impact of:

Acquisitions

(0.5) %

(0.6) %

Currency exchange rates

(1.6) %

(2.8) %

Core Sales Growth

5.0 %

7.1 %

Specialty Products & Technologies

Total sales growth

5.8 %

9.9 %

Plus the impact of:

Acquisitions

(0.8) %

(0.9) %

Currency exchange rates

(1.9) %

(3.4) %

Core Sales Growth

3.1 %

5.6 %

Equipment & Consumables

Total sales growth

9.5 %

11.8 %

Plus the impact of:

Currency exchange rates

(1.0) %

(1.9) %

Core Sales Growth

8.5 %

9.9 %

1

We use the term "core sales" to refer to GAAP revenue excluding  (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition ("acquisitions"), (2) sales from discontinued products and (3) the impact of currency translation. Sales from discontinued products includes major brands or products that Envista has made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is no longer investing in the research or development of, and (3) expects to discontinue all significant sales within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net decline of the applicable discontinued brand or product from period-to-period. The portion of GAAP revenue attributable to currency exchange rates is calculated as the difference between (a) the period-to-period change in sales and (b) the period-to-period change in sales after applying current period foreign exchange rates to the prior year period. We use the term "core sales growth" to refer to the measure of comparing current period core sales with the corresponding period of the prior year.During the first quarter of 2026, we updated our methodology for how we calculate changes in the sales price from period to period. Changes in sales prices are now calculated by comparing the current quarter sales prices to the full year sales price average from the prior year as it better reflects pricing trends over time.

Reconciliation of Operating Cash Flows to Free Cash Flow

Three Months Ended

Six Months Ended

July 3, 2026

June 27, 2025

July 3, 2026

June 27, 2025

Net operating cash (used in) provided by
operating activities

$         119.2

$          88.7

$         115.9

$          89.0

Less: payments for additions to property, plant
and equipment (capital expenditures)

(14.9)

(12.3)

(27.4)

(18.2)

Plus: proceeds from sales of property, plant
and equipment

0.8



0.9

0.5

Free Cash Flow (FCF)

$         105.1

$          76.4

$          89.4

$          71.3

FCF to Adjusted Net Income Conversion Ratio

158.0 %

174.8 %

70.7 %

83.7 %

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

ENVISTA HOLDINGS CORPORATION
NOTES TO RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)

A We exclude impairment of certain long-lived assets, executive transition costs, and cost incurred pursuant to discrete restructuring plans. 

B Represents the fair value adjustment related to inventory acquired in connection with acquisitions.

C Represents the U.S. Supreme Court's ruling to refund tariffs imposed under the International Emergency Economic Powers Act.

D Represents the settlement of certain litigation matters.

E Represents acquisition-related transaction expenses and integration costs with respect to business combinations.

F Represents losses on equity investments.

G This line item represents the aggregate tax effect of all pretax adjustments reflected in the preceding line items of the table using each adjustment's applicable tax rate, including the effect of interim tax accounting requirements of Accounting Standards Codification Topic 740 Income Taxes.

H Discrete tax matters primarily relate to excess tax benefits from stock-based compensation, changes in estimates associated with prior period uncertain tax positions and audit settlements, tax benefits resulting from a change in law, and changes in determination of realization of certain deferred tax assets.

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Envista Holdings Corporation's ("Envista" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors to:

with respect to Core Sales, identify underlying growth trends in Envista's business and compare Envista's revenue performance with prior and future periods and to Envista's peers; with respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, understand the long-term profitability trends of Envista's business and compare Envista's profitability to prior and future periods and to Envista's peers; with respect to Adjusted EBITDA, help investors understand operational factors associated with Envista's financial performance because it excludes the following from consideration:  interest, taxes, depreciation, amortization, and infrequent or unusual losses or gains such as goodwill impairment charges or nonrecurring and restructuring charges. Management uses Adjusted EBITDA, as a supplemental measure for assessing operating performance in conjunction with related GAAP amounts.  In addition, Adjusted EBITDA is used in connection with operating decisions, strategic planning, annual budgeting, evaluating Company performance and comparing operating results with historical periods and with industry peer companies; and with respect to Free Cash Flow (the "FCF Measure"), understand Envista's ability to generate cash without external financings, in order to invest and grow its business through acquisitions and other strategic opportunities. A limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire Free Cash Flow amount is not necessarily available for discretionary expenditures. Management uses these non-GAAP measures to evaluate the Company's operating and financial performance.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

With respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA: We exclude amortization of acquisition-related and other intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition.  Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies.  We believe, however, that it is important for investors to understand that such intangible assets contribute to revenue generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized. With respect to the other items excluded from Adjusted Gross Profit, Adjusted Net Income, Adjusted Operating Profit, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Envista's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult. With respect to core sales, we exclude (1) the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult, (2) sales from discontinued products because discontinued products do not have a continuing contribution to operations and management believes that excluding such items provides investors with a means of evaluating our on-going operations and facilitates comparisons to our peers, and (3) the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends. With respect to the FCF Measure, we adjust for payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to arrive at the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements. SOURCE Envista Holdings Corporation
2026-07-09 17:45 2mo ago
2026-07-09 11:31 2mo ago
Envista rostla a koupila Versah za 54,7 mil. USD
NVST Envista Holdings
FMP Stock News 78
Original source text
Key Takeaways Envista posted positive first-quarter 2026 growth across major businesses and expanded margins.NVST strengthened its dental portfolio with the Versah acquisition and continued product launches.Envista faces tariff costs, China uncertainty and foreign exchange risks despite developed market strength. Envista (NVST - Free Report)  is well-poised for growth in the coming quarters, supported by the continued execution of its three strategic priorities. Targeted acquisitions further enhance the company’s product portfolio and market position. It also benefits from strong momentum in the international markets while deepening channel penetration. Meanwhile, adverse macroeconomic impacts and currency fluctuations raise concerns for Envista’s operations.

Over the past year, this Zacks Rank #3 (Hold) stock has risen 24.2% against the 28% decline of the industry and 23.2% rise of the S&P 500 composite.

The leading optical retailer has a market capitalization of $4.41 billion. The company’s earnings yield of 5.2% is well ahead of the industry’s 3.2% yield. In the trailing four quarters, Envista delivered an average earnings surprise of 15.43%. 

Factors Supporting NVST's GrowthProgress With Strategic Priorities: Envista continues to execute on its strategy built around three areas: growth, operations and people. In the first quarter of 2026, all major businesses delivered positive growth, with 8.4% core growth in the Specialty Products & Technologies segment and 11.5% core growth in the Equipment and Consumables segment. The company has been reinvesting to support durable share gains, with sales and marketing and R&D both up double digits and new products central to results. Recent launches included Nobel S Series in implants, the Spark clear aligner launch in Japan and DEXIS software enhancements that add AI-driven workflow and diagnostics tools.

Image Source: Zacks Investment Research

The Envista Business System (“EBS”) helped drive gross margin expansion of 100 basis points and adjusted EBITDA margin growth of 120 basis points. Tariff costs increased $11 million from the prior year but were offset by supply-chain, G&A and pricing initiatives. Simultaneously, Envista is advancing its continuous improvement culture, supported by steady gains in employee engagement and talent development. The company also served 3,700 patients through the Envista Smile Project.

Value-Adding Acquisitions in Core Dental Categories: Envista continues to use M&A to broaden its clinical offering and strengthen go-to-market positions in attractive dental segments.

In first-quarter 2026, NVST acquired Versah for about $54.7 million, adding the Densah Burs system used for osseodensification, a technique intended to improve osteointegration in certain implant indications. Management expects the deal to be accretive across growth, margins and EPS, and it described synergy through Envista’s existing clinical education and commercial channels. This builds on prior acquisitions that expanded implants and imaging, including Osteogenics and the Carestream intraoral scanner business that now operates within the DEXIS portfolio and supports a more competitive implants platform over time.

International Reach and Channel Expansion: Developed markets were the key growth engine in first-quarter 2026, with North America and Europe both delivering double-digit gains. Developing markets are growing in the high single digits, excluding softness in China tied to policy uncertainty. The Spark launch in Japan adds a new growth vector in a sizable aligner market where the company already has strong orthodontic relationships, creating a cross-sell opportunity into clear aligners. Management also highlighted continued progress with DSOs and clinician education as levers to deepen penetration.

Factors Weighing on EnvistaMacro and Policy Headwinds: Management continues to flag global economic uncertainty alongside geopolitical volatility, which can weigh on dental utilization and purchasing cycles. China remains a source of uncertainty for the implants business as channel partners continue to adjust inventory levels ahead of the anticipated volume-based procurement (VBP) process, which management expects to begin between the second and third quarters. Tariffs also remain a cost headwind. First-quarter 2026 adjusted EBITDA reflected a $11 million year-over-year increase in tariff costs, with similar quarterly levels anticipated through 2026.

Foreign Exchange and Global Exposure: In the first quarter of 2026, 52.7% of Envista’s revenues came from customers outside the United States, exposing sales, margins and cash flow to currency fluctuations and regional demand variability. While balance sheet hedging has reduced quarter-to-quarter volatility compared with the prior year, foreign exchange movements continue to affect performance and can influence reported results. Regional disruptions, including conflicts in the Middle East and evolving conditions in China, add complexity to planning and may at times offset strength in developed markets.

NVST Stock Estimate TrendThe Zacks Consensus Estimate for Envista’s 2026 earnings per share (EPS) has remained constant at $1.42 in the past 60 days.

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $2.86 billion. This suggests a 5.2% increase from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are IDEXX Laboratories (IDXX - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .

IDEXX Laboratories has an earnings yield of 2.6% compared to the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. IDXX shares have rallied 2.7% against the industry’s 8.2% decline over the past year.

IDXX carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Align Technology, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 14.5% against the industry’s 10.5% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.

Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.7% against the industry’s negative 3% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 31.4% against the industry’s 8.2% decline over the past year.